T1	Participants 813 894	patients with squamous-cell carcinoma or adenocarcinoma of the thoracic esophagus
T2	Participants 951 1077	121 patients demonstrated a significant advantage for survival in the patients who received chemotherapy and radiation therapy
T3	Participants 1193 1249	patients treated with chemotherapy and radiation therapy
T4	Participants 1408 1443	patients receiving combined therapy
